J Korean Assoc Oral Maxillofac Surg 2018; 44(5): 220~224
Metachronous second primary malignancy in head and neck cancer patients: is five years of follow-up sufficient?
Mohammad Adeel1, Moghira Iqbal Siddiqi2
1Department of Surgical Oncology, Section of Head and Neck Oncology, Shaukat Khanum Memorial Cancer Hospital, Lahore,
2Department of Otolaryngology & Head and Neck Surgery, The Aga Khan University Hospital, Karachi, Pakistan
Mohammad Adeel
Department of Surgical Oncology, Section of Head and Neck Oncology, Shaukat Khanum Memorial Cancer Hospital, 7A Block R3, Johar Toen, Lahore 54782, Pakistan
TEL: +92-4235905000
E-mail: doc.adeel.khan@gmail.com
ORCID: https://orcid.org/0000-0003-0023-5566
Received October 30, 2017; Revised December 17, 2017; Accepted March 2, 2018.; Published online October 31, 2018.
© Korean Association of Oral and Maxillofacial Surgeons. All rights reserved.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Objectives: The aim of this study was to determine the incidence and characteristics of second primary malignancy (SPM) in patients with head and neck squamous cell carcinoma treated at a tertiary care hospital.
Materials and Methods: We retrospectively reviewed the medical records of 221 patients who underwent surgery with or without adjuvant treatment for head and neck cancer from 2000 to 2002. Data of age, sex, risk factors, sites of primary and SPM, TNM stage of primary tumor, incidence of SPM, and survival were collected from medical charts.
Results: Eighteen patients developed SPM during a median follow-up of 67 months, with an overall incidence of 8.14%. In addition, 77.7% of SPMs occurred in the oral cavity, followed by 11% in the lungs. The 5-year overall survival after the diagnosis of SPM in the head or neck was 70%, compared to 30% for SPM in other body regions.
Conclusion: Considering a high incidence of SPM, i.e., 8.14%, in a mean follow-up period of 67 months suggests the need for long-term follow-up. Since treatment of SPM has shown an acceptable survival rate, early detection and curative therapy should be emphasized.
Keywords: Second primary malignancy, Survivorship, Survival rate

Current Issue

31 December 2018
Vol. 44
No. 6 pp. 249~302

Indexed in